169 related articles for article (PubMed ID: 10213639)
1. Additive antiproteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy.
Russo D; Pisani A; Balletta MM; De Nicola L; Savino FA; Andreucci M; Minutolo R
Am J Kidney Dis; 1999 May; 33(5):851-6. PubMed ID: 10213639
[TBL] [Abstract][Full Text] [Related]
2. Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy.
Russo D; Minutolo R; Pisani A; Esposito R; Signoriello G; Andreucci M; Balletta MM
Am J Kidney Dis; 2001 Jul; 38(1):18-25. PubMed ID: 11431176
[TBL] [Abstract][Full Text] [Related]
3. Low-dose combination therapy with temocapril and losartan reduces proteinuria in normotensive patients with immunoglobulin a nephropathy.
Horita Y; Tadokoro M; Taura K; Suyama N; Taguchi T; Miyazaki M; Kohno S
Hypertens Res; 2004 Dec; 27(12):963-70. PubMed ID: 15894837
[TBL] [Abstract][Full Text] [Related]
4. Additive antiproteinuric effect of combined ACE inhibition and angiotensin II receptor blockade.
Ferrari P; Marti HP; Pfister M; Frey FJ
J Hypertens; 2002 Jan; 20(1):125-30. PubMed ID: 11791035
[TBL] [Abstract][Full Text] [Related]
5. Aldosterone breakthrough during therapy with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in proteinuric patients with immunoglobulin A nephropathy.
Horita Y; Taura K; Taguchi T; Furusu A; Kohno S
Nephrology (Carlton); 2006 Oct; 11(5):462-6. PubMed ID: 17014562
[TBL] [Abstract][Full Text] [Related]
6. Renoprotective effect of small doses of losartan and enalapril in patients with primary glomerulonephritis. Short-term observation.
Tylicki L; Rutkowski P; Renke M; Rutkowski B
Am J Nephrol; 2002; 22(4):356-62. PubMed ID: 12169868
[TBL] [Abstract][Full Text] [Related]
7. Additive antiproteinuric effect of ACE inhibitor and losartan in IgA nephropathy.
Bhattacharjee R; Filler G
Pediatr Nephrol; 2002 Apr; 17(4):302-4. PubMed ID: 11956889
[No Abstract] [Full Text] [Related]
8. Additive antiproteinuric effect of combination therapy with ACE inhibitor and angiotensin II receptor antagonist: differential short-term response between IgA nephropathy and diabetic nephropathy.
Kim MJ; Song JH; Suh JH; Lee SW; Kim GA
Yonsei Med J; 2003 Jun; 44(3):463-72. PubMed ID: 12833584
[TBL] [Abstract][Full Text] [Related]
9. Low-dose dual blockade of the renin-angiotensin system in patients with primary glomerulonephritis.
Rutkowski P; Tylicki L; Renke M; Korejwo G; Zdrojewski Z; Rutkowski B
Am J Kidney Dis; 2004 Feb; 43(2):260-8. PubMed ID: 14750091
[TBL] [Abstract][Full Text] [Related]
10. Antiproteinuric effect of olmesartan in patients with IgA nephropathy.
Tomino Y; Kawamura T; Kimura K; Endoh M; Hosoya T; Horikoshi S; Utsunomiya Y; Yasuda T; Toyoda M; Tsuge T; Kaneko K
J Nephrol; 2009; 22(2):224-31. PubMed ID: 19384840
[TBL] [Abstract][Full Text] [Related]
11. Effects of angiotensin-converting enzyme inhibitor, angiotensin II receptor antagonist and calcium antagonist on urinary podocytes in patients with IgA nephropathy.
Nakamura T; Ushiyama C; Suzuki S; Hara M; Shimada N; Sekizuka K; Ebihara I; Koide H
Am J Nephrol; 2000; 20(5):373-9. PubMed ID: 11092994
[TBL] [Abstract][Full Text] [Related]
12. Low-dose losartan therapy reduces proteinuria in normotensive patients with immunoglobulin A nephropathy.
Shimizu A; Takei T; Uchida K; Tsuchiya K; Nitta K
Hypertens Res; 2008 Sep; 31(9):1711-7. PubMed ID: 18971549
[TBL] [Abstract][Full Text] [Related]
13. Treatment with low-dose angiotensin-converting enzyme inhibitor (ACEI) plus angiotensin II receptor blocker (ARB) in pediatric patients with IgA nephropathy.
Yang Y; Ohta K; Shimizu M; Nakai A; Kasahara Y; Yachie A; Koizumi S
Clin Nephrol; 2005 Jul; 64(1):35-40. PubMed ID: 16047643
[TBL] [Abstract][Full Text] [Related]
14. Long-term antiproteinuric and renoprotective efficacy and safety of losartan in children with proteinuria.
Ellis D; Vats A; Moritz ML; Reitz S; Grosso MJ; Janosky JE
J Pediatr; 2003 Jul; 143(1):89-97. PubMed ID: 12915830
[TBL] [Abstract][Full Text] [Related]
15. The effects of dual blockade of the renin-angiotensin system on urinary protein and transforming growth factor-beta excretion in 2 groups of patients with IgA and diabetic nephropathy.
Song JH; Lee SW; Suh JH; Kim ES; Hong SB; Kim KA; Kim MJ
Clin Nephrol; 2003 Nov; 60(5):318-26. PubMed ID: 14640237
[TBL] [Abstract][Full Text] [Related]
16. Dual renin-angiotensin system blockade at optimal doses for proteinuria.
Laverman GD; Navis G; Henning RH; de Jong PE; de Zeeuw D
Kidney Int; 2002 Sep; 62(3):1020-5. PubMed ID: 12164886
[TBL] [Abstract][Full Text] [Related]
17. [Additive antiproteinuric effect of angiotensin II receptor antagonist and angiotensin-converting enzyme inhibitor in patients with chronic glomerulonephritis].
Iimura O; Kusano E; Tanba K; Yanagiba S; Amemiya M; Ando Y; Honma S; Muto S; Asano Y
Nihon Jinzo Gakkai Shi; 2003 Jul; 45(5):439-44. PubMed ID: 14509219
[TBL] [Abstract][Full Text] [Related]
18. Comparison of antiproteinuric effects of two different combination therapies in children with IgA nephropathy.
Yagi K; Okada M; Yanagida H; Kuwajima H; Ikeda M; Sugimoto K; Takemura T
Clin Exp Nephrol; 2003 Dec; 7(4):270-4. PubMed ID: 14712355
[TBL] [Abstract][Full Text] [Related]
19. Combined therapy of enalapril and losartan attenuates histologic progression in immunoglobulin A nephropathy.
Tanaka H; Suzuki K; Nakahata T; Tsugawa K; Konno Y; Tsuruga K; Ito E; Waga S
Pediatr Int; 2004 Oct; 46(5):576-9. PubMed ID: 15491387
[TBL] [Abstract][Full Text] [Related]
20. Combination therapy of prednisone and ACE inhibitor versus ACE-inhibitor therapy alone in patients with IgA nephropathy: a randomized controlled trial.
Lv J; Zhang H; Chen Y; Li G; Jiang L; Singh AK; Wang H
Am J Kidney Dis; 2009 Jan; 53(1):26-32. PubMed ID: 18930568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
